Results
Type
Country of origin
Qualifications

Olaparib | compare suppliers & send inquiries for free

Here you will find a list of producers, manufacturers and traders of Olaparib. You can sort by certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
Taiwan Scinopharm
Type: Producer
Produced in: Taiwan
Taiwan
China ALP PHARM
Type: Producer
Produced in: China
China
China Hunan Ouya Biological Co., Ltd.
Type: Producer
Produced in: China
China
China Beijing Mesochem Technology Co Ltd
Type: Producer
Produced in: China
China
China Changzhou Truly Foreign Trade
Type: Distributor
Produced in: China
China

Looking for Olaparib 763113-22-0?

API | Excipient name:
Olaparib 
Synonyms:
 
Cas Number:
763113-22-0 
DrugBank number:
DB09074 
Unique Ingredient Identifier:
WOH1JD9AR8

About Olaparib

Here is a short description about Olaparib. Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP. PARP enzymes are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNA repair. Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mouse xenograft models of human cancer both as monotherapy or following platinum-based chemotherapy.

Increased cytotoxicity and anti-tumor activity following treatment with olaparib were noted in cell lines and mouse tumor models with deficiencies in BRCA. In vitro studies have shown that olaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complex, resulting in disruption of cellular homeostasis and cell death. Olaparib is available as oral tablets marketed under the brand name Lynparza and was initially indicated as a maintenance therapy or monotherapy for the treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. On January 2018, FDA expanded the approved use of Lynparza to include chemotherapy-experienced patients with germline breast cancer susceptibility gene (BRCA) mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. In a randomized clinical trial involving patients with HER2-negative metastatic breast cancer with a germline BRCA mutation, the median progression-free survival for patients taking Lynparza was 7 months compared to2 months for patients taking chemotherapy only. Patient selection for this newly-approved indication can be performed based on an FDA-approved genetic test, called the BRACAnalysis CDx.

Check who is selling Olaparib in the overview above.

Olaparib manufacturers | traders | suppliers
We have 5 companies offering Olaparib from 2 different countries.

Get in contact with the supplier of your choice:

  • Changzhou Truly Foreign Trade from China
  • Scinopharm from Taiwan
  • ALP PHARM from China
  • Beijing Mesochem Technology Co Ltd from China
  • Hunan Ouya Biological Co., Ltd. from China

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.